New pill could help ITP patients who failed standard treatments

NCT ID NCT07294365

Recruiting now Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests an experimental oral drug called DZD8586 (Birelentinib) in adults with primary immune thrombocytopenia (ITP) whose condition did not improve after at least one standard therapy. About 60 participants will receive one of three dose levels to see if it safely raises platelet counts. The study aims to find a new treatment option for people with persistent or chronic ITP.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DZD8586 (Birelentinib)
What this could lead to: If it works, this could offer a new oral treatment option for people with ITP who have not responded to standard therapies.
What could go wrong: This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve platelet counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE THROMBOCYTOPENIA (ITP)

Contacts and locations

Locations

Qilu Hospital of Shandong University
RECRUITING

Jinan, Shandong, 250012, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.